Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 21, 2026, 8:05 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 121–144 of 1,571 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Biological Control Clear all
Active, not recruiting Not applicable Interventional Accepts healthy volunteers Results available

Improving Maternal and Child Health Through Prenatal Fatty Acid Supplementation

NCT02647723
View directory record Official record
Conditions
Pregnancy, Child Development
Interventions
DHA, Sugar pill
Dietary Supplement
Lead sponsor
University of Chicago
Other
Eligibility
18 Years to 34 Years · Female only
Enrollment
168 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2027
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Jul 17, 2026 · Synced Oct 21, 2026, 8:05 AM EDT
Withdrawn Phase 2 Interventional

Anakinra, COVID-19, Cytokine Storm

NCT04603742
View directory record Official record
Conditions
Covid19, Cytokine Storm, Mechanical Ventilation Complication
Interventions
Anakinra, 0.9% Saline
Drug
Lead sponsor
Weill Medical College of Cornell University
Other
Eligibility
18 Years to 89 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jan 25, 2022 · Synced Oct 21, 2026, 8:05 AM EDT
Terminated Phase 2 Interventional Results available

Study to Evaluate Adverse Events and Change in Disease Activity in Participants Between 18 to 75 Years of Age Treated With Subcutaneous (SC) Injections of ABBV-154 for Moderately to Severely Active Rheumatoid Arthritis (RA)

NCT04888585
View directory record Official record
Conditions
Rheumatoid Arthritis (RA)
Interventions
ABBV-154, Placebo
Drug
Lead sponsor
AbbVie
Industry
Eligibility
18 Years to 75 Years
Enrollment
473 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
101
States / cities
Phoenix, Arizona • Jonesboro, Arkansas • Fullerton, California + 89 more
Source: ClinicalTrials.gov public record
Updated Oct 8, 2024 · Synced Oct 21, 2026, 8:05 AM EDT
Enrolling by invitation Not applicable Interventional

Biologic Augmentation With Mesenchymal Stem Cells in Patients Undergoing Anterior Cruciate Ligament Reconstruction

NCT04650568
View directory record Official record
Conditions
Anterior Cruciate Ligament Injury, Anterior Cruciate Ligament Rupture
Interventions
Autologous Bone Marrow Derived Mesenchymal Stem Cells, Sham incision
Device · Other
Lead sponsor
Rush University Medical Center
Other
Eligibility
18 Years to 60 Years
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2027
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Jun 18, 2026 · Synced Oct 21, 2026, 8:05 AM EDT
Active, not recruiting Phase 3 Interventional Results available

A Phase III, Safety, Tolerability and Efficacy of Combination Treatment of BL-8040 and Granulocyte Colony Stimulating Factor (G-CSF) as Compared to Placebo and G-CSF for the Mobilization of Hematopoietic Stem Cells for Autologous Transplantation in Subjects With Multiple Myeloma (MM)

NCT03246529
View directory record Official record
Conditions
Multiple Myeloma
Interventions
BL-8040 1.25 mg/kg + G-CSF, Placebo +G-CSF
Drug
Lead sponsor
BioLineRx, Ltd.
Industry
Eligibility
18 Years to 78 Years
Enrollment
180 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2029
U.S. locations
10
States / cities
Los Angeles, California • Gainesville, Florida • Miami, Florida + 7 more
Source: ClinicalTrials.gov public record
Updated Jan 15, 2026 · Synced Oct 21, 2026, 8:05 AM EDT
Completed Early Phase 1 Interventional

PBI-MST-01 (NCT04541108) Substudy MSD-03: Intratumoral Microdosing of Pembrolizumab Alone and With MK-0482 or MK-4830 in HNSCC or STS

NCT06413095
View directory record Official record
Conditions
Head and Neck Squamous Cell Carcinoma, Soft Tissue Sarcoma
Interventions
Pembrolizumab, MK-0482 + Pembrolizumab, MK-4830 + Pembrolizumab
Biological · Combination Product
Lead sponsor
Presage Biosciences
Industry
Eligibility
18 Years and older
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
11
States / cities
Sacramento, California • Atlanta, Georgia • Shreveport, Louisiana + 8 more
Source: ClinicalTrials.gov public record
Updated May 14, 2024 · Synced Oct 21, 2026, 8:05 AM EDT
Completed Phase 3 Interventional Results available

Phase III Study to Evaluate Safety and Efficacy of Added Exenatide Versus Placebo to Titrated Basal Insulin Glargine in Inadequately Controlled Patients With Type II Diabetes Mellitus

NCT02229383
View directory record Official record
Conditions
Diabetes Mellitus
Interventions
Exenatide, Exenatide matching placebo
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 130 Years
Enrollment
464 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
68
States / cities
Birmingham, Alabama • Huntsville, Alabama • Muscle Shoals, Alabama + 56 more
Source: ClinicalTrials.gov public record
Updated Jan 8, 2019 · Synced Oct 21, 2026, 8:05 AM EDT
Completed Phase 3 Interventional Results available

Sargramostim, Vaccine Therapy, or Sargramostim and Vaccine Therapy in Preventing Disease Recurrence in Patients With Melanoma That Has Been Removed By Surgery

NCT01989572
View directory record Official record
Conditions
Iris Melanoma, Medium/Large Size Posterior Uveal Melanoma, Mucosal Melanoma, Ocular Melanoma With Extraocular Extension, Recurrent Melanoma, Recurrent Uveal Melanoma, Small Size Posterior Uveal Melanoma, Stage IIA Cutaneous Melanoma AJCC v6 and v7, Stage IIA Uveal Melanoma AJCC v7, Stage IIB Cutaneous Melanoma AJCC v6 and v7, Stage IIB Uveal Melanoma AJCC v7, Stage IIC Cutaneous Melanoma AJCC v6 and v7, Stage IIIA Cutaneous Melanoma AJCC v7, Stage IIIA Uveal Melanoma AJCC v7, Stage IIIB Cutaneous Melanoma AJCC v7, Stage IIIB Uveal Melanoma AJCC v7, Stage IIIC Cutaneous Melanoma AJCC v7, Stage IIIC Uveal Melanoma AJCC v7, Stage IV Cutaneous Melanoma AJCC v6 and v7, Stage IV Uveal Melanoma AJCC v7
Interventions
Laboratory Biomarker Analysis, Placebo, Sargramostim, Tyrosinase Peptide
Other · Biological
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
815 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2013
U.S. locations
148
States / cities
Birmingham, Alabama • Mobile, Alabama • Scottsdale, Arizona + 117 more
Source: ClinicalTrials.gov public record
Updated Jun 24, 2026 · Synced Oct 21, 2026, 8:05 AM EDT
Completed Phase 3 Interventional

A Study of the Safety and Efficacy Interferon-Gamma 1b in Patients With Idiopathic Pulmonary Fibrosis (IPF)

NCT00047645
View directory record Official record
Conditions
Idiopathic Pulmonary Fibrosis
Interventions
Interferon-gamma 1b
Drug
Lead sponsor
InterMune
Industry
Eligibility
20 Years to 79 Years
Enrollment
330 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2002
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Nov 2, 2007 · Synced Oct 21, 2026, 8:05 AM EDT
Not yet recruiting Early Phase 1 Interventional

BRIDGE - Blocking Receptor of IL-1β for Donor Graft Edema Reduction

NCT07410312
View directory record Official record
Conditions
Lung Transplant Recipient
Interventions
Anakinra
Drug
Lead sponsor
Northwestern University
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Aug 21, 2026 · Synced Oct 21, 2026, 8:05 AM EDT
Recruiting Phase 2 Interventional

HSCT for Patients With Fanconi Anemia Using Risk-Adjusted Chemotherapy

NCT02143830
View directory record Official record
Conditions
Fanconi Anemia, Severe Marrow Failure, Myelodysplastic Syndrome (MDS), Acute Myelogenous Leukemia (AML)
Interventions
Busulfan, Cyclophosphamide, Fludarabine, rabbit ATG, G-CSF, Peripheral blood stem cell
Drug · Biological
Lead sponsor
Children's Hospital Medical Center, Cincinnati
Other
Eligibility
3 Months and older
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2028
U.S. locations
3
States / cities
New York, New York • Cincinnati, Ohio • Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Nov 12, 2025 · Synced Oct 21, 2026, 8:05 AM EDT
Completed Phase 1Phase 2 Interventional Accepts healthy volunteers

Botulinum Toxin Type A (Botox) for the Treatment of Cervical Dystonia and Upper Thoracic Muscular Pain

NCT00178945
View directory record Official record
Conditions
Refractory Cervicothoracic Myofascial Pain Syndrome (CMPS), Cervical Dystonia
Interventions
Botulinum Toxin Type A
Drug
Lead sponsor
Vanderbilt University
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2004 – 2006
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Jun 1, 2016 · Synced Oct 21, 2026, 8:05 AM EDT
Completed Phase 3 Interventional Results available

A Study of the Efficacy and Safety of Upadacitinib (ABT-494) in Participants With Moderately to Severely Active Crohn's Disease Who Have Inadequately Responded to or Are Intolerant to Biologic Therapy

NCT03345836
View directory record Official record
Conditions
Crohn's Disease
Interventions
Matching Placebo for Upadacitinib, Upadacitinib
Drug
Lead sponsor
AbbVie
Industry
Eligibility
18 Years to 75 Years
Enrollment
624 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2021
U.S. locations
119
States / cities
Mobile, Alabama • Chandler, Arizona • Scottsdale, Arizona + 92 more
Source: ClinicalTrials.gov public record
Updated Aug 15, 2022 · Synced Oct 21, 2026, 8:05 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Safety and Efficacy Study of Fluzone® Vaccine Combined With Different Doses of JVRS-100 Adjuvant

NCT00662272
View directory record Official record
Conditions
Influenza
Interventions
Fluzone vaccine with JVRS-100 adjuvant, Fluzone vaccine
Biological
Lead sponsor
Colby Pharmaceutical Company
Industry
Eligibility
18 Years to 49 Years
Enrollment
128 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2009
U.S. locations
2
States / cities
Miami, Florida • Lenexa, Kansas
Source: ClinicalTrials.gov public record
Updated Mar 17, 2010 · Synced Oct 21, 2026, 8:05 AM EDT
Not yet recruiting Not applicable Interventional Accepts healthy volunteers

Investigation of Motorized Lower-limb Prostheses

NCT07584707
View directory record Official record
Conditions
Ambulation With the "Take Home" or Passive Prosthesis, Ambulation With the Motorized Prosthesis in the "Off" Configuration, Ambulation With the Motorized Prosthesis in the "Transparent" Condition, Ambulation With the Motorized Prosthesis in the "Powered" Condition
Interventions
Passive prosthesis, Motorized prosthesis
Device
Lead sponsor
Northern Arizona University
Other
Eligibility
18 Years to 85 Years
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2029
U.S. locations
1
States / cities
Flagstaff, Arizona
Source: ClinicalTrials.gov public record
Updated May 13, 2026 · Synced Oct 21, 2026, 8:05 AM EDT
Terminated Phase 1 Interventional

Placebo Controlled Study of Fecal Microbiota Transplant (FMT) for a First or Second Episode of C. Difficile Infection in Adults Using a Frozen Encapsulated Inoculum

NCT02343328
View directory record Official record
Conditions
Clostridium Difficile
Interventions
Fecal Microbiota Transplant, Placebo
Biological
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years and older
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Sep 13, 2017 · Synced Oct 21, 2026, 8:05 AM EDT
Completed Phase 2Phase 3 Interventional Accepts healthy volunteers

The Efficacy and Molecular Mechanism of Botulinum Toxin in the Reduction of Breast Reduction Mammoplasty Scar Formation

NCT03887377
View directory record Official record
Conditions
Scar, Hypertrophic Scar, Mammary Disorder
Interventions
Botulinum Toxins, Normal saline
Drug · Other
Lead sponsor
Henry Ford Health System
Other
Eligibility
18 Years to 65 Years · Female only
Enrollment
22 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2024
U.S. locations
1
States / cities
Detroit, Michigan
Source: ClinicalTrials.gov public record
Updated Jun 15, 2025 · Synced Oct 21, 2026, 8:05 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Optimization of the Bowel Preparation Regimen for the PillCam® COLON 2 Capsule Endoscopy Procedure

NCT02481219
View directory record Official record
Conditions
Colorectal Cancer Screening
Interventions
PillCam® COLON 2 procedure-CONTROL, Senna tablets, PEG, Metoclopramide, Erythromycin, SUPREP oral sulfate solution, Bisacodyl, SUPREP oral sulfate solution with Gastrografin
Device · Drug
Lead sponsor
Medtronic - MITG
Industry
Eligibility
50 Years to 75 Years
Enrollment
122 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2016
U.S. locations
6
States / cities
Anniston, Alabama • Indianapolis, Indiana • Dayton, Ohio + 2 more
Source: ClinicalTrials.gov public record
Updated Mar 7, 2017 · Synced Oct 21, 2026, 8:05 AM EDT
Terminated Phase 1 Interventional

Trial of OnabotulinumtoxinA for Depression in Parkinson Disease

NCT03069911
View directory record Official record
Conditions
Parkinson Disease, Depression
Interventions
OnabotulinumtoxinA, Control
Biological
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years to 95 Years
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Aug 6, 2019 · Synced Oct 21, 2026, 8:05 AM EDT
Recruiting Phase 3 Interventional

Efficacy and Safety of 4F-PCC (4-Factor Prothrombin Complex Concentrate) in Adult Patients Undergoing Complex Cardiovascular Surgery With Cardiopulmonary Bypass (CPB)

NCT07094087
View directory record Official record
Conditions
Complex Cardiovascular Surgery With Cardiopulmonary Bypass
Interventions
BE1116, FFP
Biological
Lead sponsor
CSL Behring
Industry
Eligibility
18 Years and older
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
16
States / cities
Los Angeles, California • Atlanta, Georgia • Chicago, Illinois + 12 more
Source: ClinicalTrials.gov public record
Updated Oct 15, 2026 · Synced Oct 21, 2026, 8:05 AM EDT
Completed Phase 3 Interventional Results available

GLP-1 Receptor Agonist Lixisenatide Versus Exenatide in Patients With Type 2 Diabetes for Glycemic Control and Safety Evaluation, on Top of Metformin

NCT00707031
View directory record Official record
Conditions
Diabetes Mellitus, Type 2
Interventions
Lixisenatide (AVE0010), Pen auto-injector, Exenatide, Prefilled pen injector, Metformin
Drug · Device
Lead sponsor
Sanofi
Industry
Eligibility
18 Years and older
Enrollment
639 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
1
States / cities
Bridgewater, New Jersey
Source: ClinicalTrials.gov public record
Updated Dec 2, 2016 · Synced Oct 21, 2026, 8:05 AM EDT
Not yet recruiting Phase 2Phase 3 Interventional Accepts healthy volunteers

Impact of Standardization on Outcomes Following Cervical Ripening

NCT07576881
View directory record Official record
Conditions
Pregnancy
Interventions
Cervical Ripening with a double balloon catheter only, Cervical ripening with a double balloon catheter plus misoprostol, Usual-care control group
Device · Combination Product
Lead sponsor
Indiana University
Other
Eligibility
18 Years and older · Female only
Enrollment
1,158 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2028
U.S. locations
1
States / cities
Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated May 8, 2026 · Synced Oct 21, 2026, 8:05 AM EDT
Completed Early Phase 1 Interventional Accepts healthy volunteers

PPG Project 3 - PET/MRI of the Brain-hematopoiesis-atherosclerosis Axis in PTSD Patients

NCT03279393
View directory record Official record
Conditions
PTSD, Trauma, Healthy
Interventions
fluorodeoxyglucose (FDG)-PET/MRI
Drug
Lead sponsor
Zahi Fayad
Other
Eligibility
30 Years to 65 Years
Enrollment
190 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2023
U.S. locations
2
States / cities
Boston, Massachusetts • New York, New York
Source: ClinicalTrials.gov public record
Updated Apr 14, 2023 · Synced Oct 21, 2026, 8:05 AM EDT
Completed No phase listed Observational Accepts healthy volunteers Results available

Persistence of Bactericidal Antibodies in Adolescents and Adults Who Had Received a Single Dose of Menactra® Vaccine

NCT00862277
View directory record Official record
Conditions
Meningococcal Infections, Meningitis
Interventions
Menactra®, Menomune®
Biological
Lead sponsor
Sanofi Pasteur, a Sanofi Company
Industry
Eligibility
14 Years to 27 Years
Enrollment
763 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2009
U.S. locations
20
States / cities
Little Rock, Arkansas • Fountain Valley, California • Marietta, Georgia + 15 more
Source: ClinicalTrials.gov public record
Updated Apr 14, 2016 · Synced Oct 21, 2026, 8:05 AM EDT